Epstein-Barr Virus Breakthrough: How Scientists Will Stop It

Key Takeaways

• Epstein-Barr virus (EBV) infects roughly 95% of the global adult population, making it one of the most widespread human infections.
• A 2022 study published in Science by Bjornevik et al. found strong evidence linking EBV to multiple sclerosis, shifting decades of speculation into measurable risk data.
• Researchers at Stanford and Harvard have identified specific molecular mechanisms, particularly the EBNA2 protein, that may explain how EBV triggers autoimmune damage in genetically susceptible people.
• No approved EBV vaccine exists yet, but several candidates are in clinical trials, and understanding the mechanism opens new paths for prevention.

Ninety-five percent of adults worldwide carry Epstein-Barr virus, and for most people it causes nothing more than a brief fever or no symptoms at all. But that near-universal infection has quietly been implicated in something far more serious. A growing body of evidence, headlined by a large longitudinal study published in Science in January 2022, now suggests that EBV is a leading trigger for multiple sclerosis. The finding reframes a virus most people barely think about as one of the most consequential infectious agents in modern neurology.

What is Epstein-Barr virus, and why does it matter?

EBV is a member of the herpesvirus family, specifically human herpesvirus 4. It spreads primarily through saliva, which is why infectious mononucleosis, the illness most commonly associated with EBV, earned the nickname “the kissing disease” decades ago. Primary infection typically occurs in childhood in low- and middle-income settings, including much of South Asia, where seroprevalence approaches 90% by age five. In higher-income countries, infection often delays into adolescence or early adulthood, when it is more likely to present as mono.

After the initial infection, EBV does not leave the body. It establishes lifelong latency in B lymphocytes, a type of white blood cell. The immune system keeps it in check, but the virus persists. For the vast majority of carriers, this arrangement causes no problems. The trouble begins when the virus interacts with specific genetic risk factors in ways scientists are only now beginning to map.

The study that changed the conversation

The paper that shifted the field came from Bjornevik et al. at the Harvard T.H. Chan School of Public Health, published in Science on January 13, 2022. The research team analyzed serum samples from over 10 million active-duty US military personnel collected over a 20-year period. They identified 955 individuals who developed multiple sclerosis during their service and tracked their EBV status over time.

The results were striking. Of those who developed MS, 801 were initially EBV-negative at the time of their first sample. Of those 801, all but one seroconverted to EBV-positive before their MS diagnosis. The hazard ratio for MS after EBV infection was 32.4, a figure so large it effectively ruled out coincidence. By contrast, infection with other viruses, including cytomegalovirus, showed no such association.

What struck me about this data was not just the magnitude of the association but the study’s design. Because the researchers had serial blood samples collected before any MS diagnosis, they could establish temporal sequence. EBV infection preceded MS. That is not the same as proving causation, but it is the strongest observational evidence anyone had produced in decades of investigating this link.

How EBV might trigger autoimmunity

The Bjornevik paper established the association. A separate line of research has been working on the mechanism. A study led by William Robinson and Lawrence Steinman at Stanford, published in Nature in 2022, identified a specific molecular mimicry pathway. The EBV protein EBNA2 shares structural similarities with GlialCAM, a protein expressed on glial cells in the central nervous system. Antibodies generated against EBNA2 can cross-react with GlialCAM, essentially training the immune system to attack the body’s own neural tissue.

This mechanism fits within a broader understanding of how infections can trigger autoimmune disease. The concept of molecular mimicry has been discussed for years, but having a specific viral protein and a specific human protein identified gives researchers something concrete to target. It also helps explain why only a small fraction of EBV carriers develop MS. The cross-reactivity appears to depend on specific HLA gene variants, particularly HLA-DRB1*15:01, which is already the strongest known genetic risk factor for MS.

Robinson and Steinman’s team examined B cells and plasma cells from the cerebrospinal fluid of MS patients and found that antibodies targeting EBNA2 also bound GlialCAM. The finding was consistent across multiple patient cohorts. It does not close the case, but it provides a plausible biological pathway from infection to disease.

Where the science stands now

The World Health Organization currently lists MS as a non-communicable neurological condition affecting approximately 2.8 million people globally. The WHO does not classify EBV as a confirmed cause of MS, but the organization acknowledges the emerging evidence and the need for continued research. The National Multiple Sclerosis Society has funded research into the EBV-MS link for years and called the Bjornevik findings a significant step forward.

It is worth being honest about what remains unknown. The 32.4 hazard ratio is from a military cohort that skews young, healthy, and predominantly male. Whether the same magnitude holds across different populations, including those in South Asia where EBV infection occurs much earlier in life, has not been confirmed. The molecular mimicry mechanism is compelling but has not been demonstrated in animal models with the rigor needed to claim a complete causal chain. And no one has yet shown that preventing EBV infection prevents MS, though that is the logical next question.

What can be done: vaccines and future directions

Several EBV vaccine candidates are in development. Moderna began a Phase I clinical trial of an mRNA-based EBV vaccine in early 2022, building on the platform technology used for its COVID-19 vaccine. The National Institute of Allergy and Infectious Diseases is also conducting early-stage trials of a different candidate. Neither is close to regulatory approval, but the existence of multiple candidates signals that the field takes the MS link seriously.

From a public health perspective, the implications extend beyond MS. EBV is also associated with certain lymphomas, nasopharyngeal carcinoma, and gastric cancer. A vaccine that prevented primary EBV infection could reduce the burden of several cancers in addition to autoimmune disease. In regions like southern China and parts of Southeast Asia, where nasopharyngeal carcinoma rates are elevated, the impact could be substantial.

However, no vaccine will be available for years. In the meantime, the most productive response to this research is continued surveillance, funding for clinical trials, and honest communication about what the evidence shows and what it does not. The Bjornevik study and the Robinson-Steinman mechanism work together to build a case that EBV is necessary but not sufficient for MS. That distinction matters. Most people who carry EBV will never develop MS, and understanding why some do and most do not is where the next decade of research will focus.

I keep coming back to the gap between how common this infection is and how little public awareness exists around its potential consequences. Ninety-five percent of humans carry this virus, and scientists just found how to stop it, or at least how to start thinking about stopping it. The path from a 32.4 hazard ratio to a licensed vaccine is long, but for the first time, the direction is clear.

Sources

1. Bjornevik K, Cortese M, Healy BC, et al. Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis. Science. 2022;375(6578):296-301. doi:10.1126/science.abj8222. PMID: 35025605.

2. Lanz TV, Brewer RC, Steinman L, Robinson WH. Clonally expanded B cells in multiple sclerosis bind EBV EBNA2 and GlialCAM. Nature. 2022;603(7900):321-327. doi:10.1038/s41586-022-04432-9. PMID: 35073561.

3. World Health Organization. Multiple Sclerosis Fact Sheet. Updated 2023. Accessed via who.int.

4. Robinson WH, Steinman L. Epstein-Barr virus and multiple sclerosis. Science. 2022;375(6578):264-265. doi:10.1126/science.abm7930. PMID: 35025604.

5. National Institute of Allergy and Infectious Diseases. Epstein-Barr Virus (EBV) Vaccine Clinical Trial. National Institutes of Health. 2022. Accessed via niaid.nih.gov.

6. Dunmire SK, Verghese PS, Balfour HH. Primary Epstein-Barr virus infection. J Clin Virol. 2018;102:84-92. doi:10.1016/j.jcv.2018.03.001. PMID: 29525635.

This article is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations. Consult a qualified healthcare provider for any health concerns. See our Medical Disclaimer.